Credit: Original article published here.DocWire News recently spoke with Dr. Richard Pitts, Chief Medical Officer of CalOptima Health, a major managed care plan in California on the health plan’s recent announcement of a ‘cancer moonshot’ for under resourced communities. CalOptima is investing a record $50 million over the next five years into 26 community health centers across Orange County in an effort to spur measurable improvements in patient experience and outcomes. See what Dr. Pitts had to say about this exciting news.

Credit: Original article published here.DocWire News Medical Lead Dr. Payal Kohli reviewed the REDUCE-IT trial, which demonstrated that icosapent ethyl intervention twice daily is superior to placebo in reducing triglycerides (TGs), cardiovascular events, as well as CV mortality in patients with high TGs and either known CVD or individuals with known CVD or at high risk for developing it, and patients on statin therapy with relatively well-controlled LDL levels. The study was presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology (ACC.23/WCC).

Credit: Original article published here.DocWire News recently spoke with Allen Davidoff, Ph.D., the CEO of XORTX Therapeutics (pronounced Zor-tex). XORTX is developing novel therapies for progressive kidney disease. The company is planning to launch a Phase 3 study for its lead candidate, oxypurinol, in patients with the rare disease Autosomal Dominant Polycystic Kidney Disease (ADPKD), with plans to expand to diabetic nephropathy (kidney failure in diabetes patients) and more. This is on the heels of recently presented preclinical data validating the proof of concept for oxypurinol. Dr. Davidoff spoke to us in-depth about the company he helms, and how they aim to combat progressive kidney disease.